PT Kalbe Farma Tbk KLBF

IDX · Indonesia · Health Technology

IDR 720.00-10.00 (-1.37%)

Market closed· Oct 1, 2026, 9:14 AM UTC· IDR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

PT Kalbe Farma Tbk KLBF

IDX · Indonesia · Health Technology

IDR 720.00-10.00 (-1.37%)

Market closed· Oct 1, 2026, 9:14 AM UTC· IDR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-26.53% · 6MFull-screen chart

Open IDR 720.00High IDR 730.00Low IDR 715.00Close IDR 720.00Volume 46.87M

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: IDR 730.00
Day range: IDR 715.00 – IDR 730.00
52-week range: IDR 630.00 – IDR 1,345.00
Volume: 46.87M
Market cap: IDR 34.17T
P/E (TTM): 9.0
Dividend yield (annualized): 2.74%
Next earnings date: 2026-11-03
Avg. volume (1Y): 80.40M

Performance

1 week

-2.04%

1 month

-7.10%

3 months

-4.00%

6 months

-22.89%

Year to date

-38.57%

1 year

-32.70%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Indonesia
Exchange: IDX
Shares outstanding: 45.25B
Employees: 12,835
ISIN: ID1000125107
Beta: 0.55

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceDec 11, 2025

Kalbe Farma and LIFE AI Unveil StrokeGENME to Personalize Stroke Prevention at National Scale

SINGAPORE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- In a pioneering advancement that aims to reduce the increasing problem of strokes, PT Kalbe Farma Tbk - the largest publicly listed pharmaceutical company in Southeast Asia - through its subsidiary Kalgen Innolab Clinical Laboratory (Innolab) has announced StrokeGENME, a genetics-powered platform that translates DNA insights into individualized stroke-prevention plans, delivered through Kalbe’s nationwide ecosystem. Indonesia’s leading healthcare ente

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.